Story perspectives

FDA Approves Moderna's mNEXSPIKE Vaccine for Vulnerable Adults

6/1/2025

41 8

Summary

Story summary

The FDA has greenlit Moderna's mNEXSPIKE COVID-19 vaccine for adults 65 and older, as well as those aged 12-64 with health risks. Boasting greater efficacy than Spikevax, mNEXSPIKE is set to launch in the 2025-2026 season, reinforcing Moderna's commitment to safeguarding public health.

1 of 1

Story summary

The FDA has greenlit Moderna's mNEXSPIKE COVID-19 vaccine for adults 65 and older, as well as those aged 12-64 with health risks. Boasting greater efficacy than Spikevax, mNEXSPIKE is set to launch in the 2025-2026 season, reinforcing Moderna's commitment to safeguarding public health.